Loading…
BioLineRx Ltd. is projected to rise to $2.79 by 2027, a +5% move from its current price of $2.66. BLRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.59 | $2.66 | $2.73 | -0.01% |
| Aug 6 | $2.56 | $2.66 | $2.75 | -0.02% |
| Aug 7 | $2.54 | $2.66 | $2.78 | -0.03% |
| Aug 8 | $2.52 | $2.66 | $2.80 | -0.04% |
| Aug 9 | $2.51 | $2.66 | $2.81 | -0.05% |
| Aug 10 | $2.49 | $2.66 | $2.83 | -0.05% |
| Aug 11 | $2.48 | $2.66 | $2.84 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.48 | $2.66 | $2.84 | -0.06% |
| Week 2 | $2.41 | $2.65 | $2.92 | -0.13% |
| Week 3 | $2.36 | $2.65 | $2.98 | -0.19% |
| Week 4 | $2.32 | $2.65 | $3.03 | -0.26% |
| Week 5 | $2.28 | $2.65 | $3.08 | -0.32% |
| Week 6 | $2.24 | $2.65 | $3.12 | -0.38% |
| Week 7 | $2.21 | $2.65 | $3.16 | -0.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioLineRx Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for oncology and rare diseases.
Its pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi’in, Israel.
BioLineRx Ltd. (BLRX) is a healthcare stock. Current price: $2.83.
The company’s market capitalization is $12.73M and its rank is 4735, reflecting its position among small-cap healthcare stocks.
The forecast suggests a neutral near-term path with limited gains through 2029, followed by a bullish trajectory from 2030 onward. By 2030, the average forecast price is $3.40 with a max of $5.02 and a min of $2.49, and by 2050 the average forecast price reaches $12.56 with a max of $23.85 and a min of $6.87, indicating meaningful upside over the longer term.
A major floor 18.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 26.8% above — a clean break opens room to run.
A major ceiling 42.3% above — clearing it would confirm fresh momentum.
Key BLRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BLRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.78 | Sell | $2.79 | Sell |
| MA 10 | $2.82 | Sell | $2.83 | Sell |
| MA 20 | $2.93 | Sell | $2.91 | Sell |
| MA 50 | $3.12 | Sell | $2.98 | Sell |
| MA 100 | $2.85 | Sell | $2.98 | Sell |
| MA 200 | $3.00 | Sell | $3.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.97 | Neutral |
| Stoch RSI (14) | 72.61 | Neutral |
| CCI (20) | -62.79 | Neutral |
| Williams %R (14) | -65.71 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -3.09 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 34.29 | Neutral |
| TRIX (15) | -0.41 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 40.83 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 2.73 | Sell |
| ADX (14) | 15.35 | Neutral |
| ATR (14) | 0.07 | Info |
The near-term technical picture remains NEUTRAL.
RSI14 is 40, and the 50-day simple moving average is $3.15 while the 200-day simple moving average is $3.06, suggesting modest momentum and a price range around the moving averages.
Support is at $2.83 and resistance at $3.47. The 30-day trading range spans from $2.33 to $3.43, and annualized volatility is 60.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.18 | $2.66 | $3.36 | 0% | Neutral | |
| $2.24 | $2.79 | $3.67 | +5% | Neutral | |
| $2.32 | $2.97 | $4.05 | +12% | Neutral | |
| $2.34 | $3.06 | $4.28 | +15% | Neutral | |
| $2.64 | $3.52 | $5.04 | +32% | Bullish | |
| $3.02 | $4.10 | $5.99 | +54% | Bullish | |
| $3.27 | $4.50 | $6.71 | +69% | Bullish | |
| $3.30 | $4.62 | $6.99 | +74% | Bullish | |
| $3.10 | $4.40 | $6.76 | +66% | Bullish | |
| $3.35 | $4.81 | $7.51 | +81% | Bullish | |
| $4.46 | $6.82 | $11.28 | +157% | Bullish | |
| $8.22 | $13.96 | $25.17 | +425% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.18 | $2.66 | $3.27 | +0.00% |
| September 2026 | $2.29 | $2.71 | $3.28 | +1.89% |
| October 2026 | $2.22 | $2.63 | $3.23 | -2.67% |
| November 2026 | $2.23 | $2.67 | $3.29 | +1.21% |
| December 2026 | $2.26 | $2.71 | $3.36 | +1.48% |
Click any year to see its month-by-month BLRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BLRX is projected to trade between $2.18 and $3.36, averaging $2.66 — a potential gain of 0% from today's $2.66. A consolidation phase looks the most probable path here.
BioLineRx Ltd.'s 2027 outlook centres on $2.79, within a $2.24 to $3.67 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2028, BLRX could reach as high as $4.05, with a base case around $2.97 and support toward $2.32 — roughly +12% from $2.66. A consolidation phase looks the most probable path here.
Expect BLRX to range from $2.34 to $4.28 through 2029. The $3.06 average target implies a +15% move from current prices. That is up +3% on the projected 2028 average. Price action looks broadly range-bound.
The BLRX price prediction for 2030 points to an average of $3.52 (low $2.64, high $5.04) — a potential gain of +32% on today's $2.66. Buyers look set to stay in control over this stretch.
In 2031, BLRX is projected to trade between $3.02 and $5.99, averaging $4.10 — a potential gain of +54% from today's $2.66. That is up +16% on the projected 2030 average. Momentum favours further upside here.
BioLineRx Ltd.'s 2032 outlook centres on $4.50, within a $3.27 to $6.71 range. That is up +10% on the projected 2031 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BLRX could reach as high as $6.99, with a base case around $4.62 and support toward $3.30 — roughly +74% from $2.66. Momentum favours further upside here.
Expect BLRX to range from $3.10 to $6.76 through 2034. The $4.40 average target implies a +66% move from current prices. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The BLRX price prediction for 2035 points to an average of $4.81 (low $3.35, high $7.51) — a potential gain of +81% on today's $2.66. Momentum favours further upside here.
In 2040, BLRX is projected to trade between $4.46 and $11.28, averaging $6.82 — a potential gain of +157% from today's $2.66. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioLineRx Ltd.'s 2050 outlook centres on $13.96, within a $8.22 to $25.17 range. That is up +105% on the projected 2040 average. That marks a +425% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BLRX today (≈ 376.364321 BLRX) could be worth
$5,253.61
+$4,253.61 (+425%) by 2050 · US Dollar
Based on the average projected BLRX price of $13.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BLRXwould be worth at today's price.
$1,000 invested in BLRX on Jul 31, 2025 (≈ 251.25628 BLRX) would be worth
$667.59
-$332.41 (-33.2%) today · 0.67× · US Dollar
Based on a BLRX entry price of $3.98 vs. today's $2.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.82 | $942.2 | -5.8% |
| 1 month ago | $3.17 | $838.17 | -16.2% |
| 3 months ago | $2.86 | $929.02 | -7.1% |
| 6 months ago | $3.01 | $882.72 | -11.7% |
| 1 year ago | $3.98 | $667.59 | -33.2% |
| All time (5.0y) ago | $126 | $21.09 | -97.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BLRX forecast.
Our base-case forecast reaches $5.30 around 2040.
Implied market cap at $5.30: $23.06M
The multi-year forecast shows a bullish trend developing from 2030 onward, with steady upside through 2050.
In 2030 the avg price is $3.40 with min $2.49 and max $5.02; ROI 20.2; sentiment BULLISH.
In 2040 the avg price is $6.37 with min $3.96 and max $11.01; ROI 125.2; sentiment BULLISH.
In 2050 the avg price is $12.56 with min $6.87 and max $23.85; ROI 343.8; sentiment BULLISH.
These figures are estimates and not guarantees; actual results may differ due to market, regulatory, and company-specific factors.
Tap a question to reveal the answer.
2030 min $2.49; avg $3.40; max $5.02; ROI 20.2; sentiment BULLISH.
Forecasts show neutral momentum through 2029, followed by bullish momentum from 2030 onward. In 2030 the avg is $3.40 and by 2050 the avg is $12.56 with ROI 343.8; earlier years (2026-2029) show modest gains (e.g., 2026 avg $2.83, ROI 0; 2027 avg $2.87, ROI 1.3; 2028 avg $3.09, ROI 9.1; 2029 avg $2.98, ROI 5.2). These are estimates and not guarantees.
Yes. The 2040 forecast shows min $3.96, avg $6.37, max $11.01 with ROI 125.2 and sentiment BULLISH.
Current price: $2.83. Market cap: $12.73M.
Sentiment NEUTRAL. RSI14 is 40. SMA50 is $3.15 and SMA200 is $3.06. Support is at $2.83 and resistance at $3.47. The 30-day range is $2.33 to $3.43. Annualized volatility is 60.
BioLineRx Ltd. Community Discussion
0Share your BioLineRx Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.